Puneeth Iyengar is an Attending, Director of the Metastatic Service, and Member of the Thoracic Service in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. He has also Co-leader of the MSKCC Bone Metastasis Program, Member of the Druckenmiller Center for Lung Cancer Research, and Adjunct Faculty at UT Southwestern Medical Center in Dallas. He has led programs investigating the use of local therapy (SBRT) in the setting of oligometastatic NSCLC (Iyengar et al, JCO 2014, Iyengar et al, JAMA Oncology 2017), hypofractionated therapies for stage III NSCLC (Iyengar et al, JAMA Oncology 2021) and is principal investigator of NRG LU 002, a phase II/III randomized trial assessing the benefits of immunotherapy -/+ local therapy on overall survival for stage IV NSCLC. Dr. Iyengar also runs an independent NIH-funded research laboratory studying cancer cachexia from a basic science and translational perspective. The preclinical studies on cancer cachexia have led to multiple Ph1 and RPh2 clinical trials. Dr. Iyengar trained at MD Anderson Cancer Center and received his MD, PhD degrees at Albert Einstein College of Medicine (NYC) and Bachelor of Science at MIT.